These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 33939252)

  • 1. Targeted dual inhibition of c-Met/VEGFR2 signalling by foretinib improves antitumour effects of nanoparticle paclitaxel in gastric cancer models.
    Grojean M; Schwarz MA; Schwarz JR; Hassan S; von Holzen U; Zhang C; Schwarz RE; Awasthi N
    J Cell Mol Med; 2021 Jun; 25(11):4950-4961. PubMed ID: 33939252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer.
    Shah MA; Wainberg ZA; Catenacci DV; Hochster HS; Ford J; Kunz P; Lee FC; Kallender H; Cecchi F; Rabe DC; Keer H; Martin AM; Liu Y; Gagnon R; Bonate P; Liu L; Gilmer T; Bottaro DP
    PLoS One; 2013; 8(3):e54014. PubMed ID: 23516391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The dual PI3K/mTOR inhibitor NVP-BEZ235 enhances nab-paclitaxel antitumor response in experimental gastric cancer.
    Zhang CΗ; Awasthi N; Schwarz MA; Schwarz RE
    Int J Oncol; 2013 Nov; 43(5):1627-35. PubMed ID: 24042258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination effect of lapatinib with foretinib in HER2 and MET co-activated experimental esophageal adenocarcinoma.
    Hassan MS; Williams F; Awasthi N; Schwarz MA; Schwarz RE; Li J; von Holzen U
    Sci Rep; 2019 Nov; 9(1):17608. PubMed ID: 31772236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Foretinib inhibits angiogenesis, lymphangiogenesis and tumor growth of pancreatic cancer in vivo by decreasing VEGFR-2/3 and TIE-2 signaling.
    Chen HM; Tsai CH; Hung WC
    Oncotarget; 2015 Jun; 6(17):14940-52. PubMed ID: 25909285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks.
    Kataoka Y; Mukohara T; Tomioka H; Funakoshi Y; Kiyota N; Fujiwara Y; Yashiro M; Hirakawa K; Hirai M; Minami H
    Invest New Drugs; 2012 Aug; 30(4):1352-60. PubMed ID: 21655918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Foretinib (GSK1363089), an orally available multikinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces anoikis, and impairs ovarian cancer metastasis.
    Zillhardt M; Park SM; Romero IL; Sawada K; Montag A; Krausz T; Yamada SD; Peter ME; Lengyel E
    Clin Cancer Res; 2011 Jun; 17(12):4042-51. PubMed ID: 21551255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER2 Confers Resistance to Foretinib Inhibition of MET-Amplified Esophageal Adenocarcinoma Cells.
    Goltsov AA; Fang B; Pandita TK; Maru DM; Swisher SG; Hofstetter WL
    Ann Thorac Surg; 2018 Feb; 105(2):363-370. PubMed ID: 29223420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted FGFR/VEGFR/PDGFR inhibition with dovitinib enhances the effects of nab-paclitaxel in preclinical gastric cancer models.
    Crawford K; Bontrager E; Schwarz MA; Chaturvedi A; Lee DD; Md Sazzad H; von Holzen U; Zhang C; Schwarz RE; Awasthi N
    Cancer Biol Ther; 2021 Dec; 22(10-12):619-629. PubMed ID: 34882068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Augmentation of
    Awasthi N; Schwarz MA; Zhang C; Schwarz RE
    Mol Cancer Ther; 2018 Nov; 17(11):2353-2364. PubMed ID: 30166402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Foretinib demonstrates anti-tumor activity and improves overall survival in preclinical models of hepatocellular carcinoma.
    Huynh H; Ong R; Soo KC
    Angiogenesis; 2012 Mar; 15(1):59-70. PubMed ID: 22187171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic effects of foretinib with HER-targeted agents in MET and HER1- or HER2-coactivated tumor cells.
    Liu L; Shi H; Liu Y; Anderson A; Peterson J; Greger J; Martin AM; Gilmer TM
    Mol Cancer Ther; 2011 Mar; 10(3):518-30. PubMed ID: 21252284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. c-Met inhibitors attenuate tumor growth of small cell hypercalcemic ovarian carcinoma (SCCOHT) populations.
    Otte A; Rauprich F; von der Ohe J; Yang Y; Kommoss F; Feuerhake F; Hillemanns P; Hass R
    Oncotarget; 2015 Oct; 6(31):31640-58. PubMed ID: 26436697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Augmentation of response to nab-paclitaxel by inhibition of insulin-like growth factor (IGF) signaling in preclinical pancreatic cancer models.
    Awasthi N; Scire E; Monahan S; Grojean M; Zhang E; Schwarz MA; Schwarz RE
    Oncotarget; 2016 Jul; 7(30):46988-47001. PubMed ID: 27127884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Foretinib is effective therapy for metastatic sonic hedgehog medulloblastoma.
    Faria CC; Golbourn BJ; Dubuc AM; Remke M; Diaz RJ; Agnihotri S; Luck A; Sabha N; Olsen S; Wu X; Garzia L; Ramaswamy V; Mack SC; Wang X; Leadley M; Reynaud D; Ermini L; Post M; Northcott PA; Pfister SM; Croul SE; Kool M; Korshunov A; Smith CA; Taylor MD; Rutka JT
    Cancer Res; 2015 Jan; 75(1):134-46. PubMed ID: 25391241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual blockade of MET and VEGFR2 signaling pathways as a potential therapeutic maneuver for peritoneal carcinomatosis in scirrhous gastric cancer.
    Kasai S; Kuwayama N; Motoo Y; Kawashima A; Matsumoto K; Yano S; Matsushima K; Yasumoto K
    Biochem Biophys Res Commun; 2022 Apr; 600():80-86. PubMed ID: 35196631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Foretinib induces G2/M cell cycle arrest, apoptosis, and invasion in human glioblastoma cells through c-MET inhibition.
    Gortany NK; Panahi G; Ghafari H; Shekari M; Ghazi-Khansari M
    Cancer Chemother Pharmacol; 2021 Jun; 87(6):827-842. PubMed ID: 33688998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2.
    Eder JP; Shapiro GI; Appleman LJ; Zhu AX; Miles D; Keer H; Cancilla B; Chu F; Hitchcock-Bryan S; Sherman L; McCallum S; Heath EI; Boerner SA; LoRusso PM
    Clin Cancer Res; 2010 Jul; 16(13):3507-16. PubMed ID: 20472683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.
    Choueiri TK; Vaishampayan U; Rosenberg JE; Logan TF; Harzstark AL; Bukowski RM; Rini BI; Srinivas S; Stein MN; Adams LM; Ottesen LH; Laubscher KH; Sherman L; McDermott DF; Haas NB; Flaherty KT; Ross R; Eisenberg P; Meltzer PS; Merino MJ; Bottaro DP; Linehan WM; Srinivasan R
    J Clin Oncol; 2013 Jan; 31(2):181-6. PubMed ID: 23213094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET.
    Xiang Q; Chen W; Ren M; Wang J; Zhang H; Deng DY; Zhang L; Shang C; Chen Y
    Clin Cancer Res; 2014 Jun; 20(11):2959-70. PubMed ID: 24700742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.